Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Drug Watch” Sent Back To The Drawing Board; FDA Turning To MedWatch?

Executive Summary

FDA is considering proactive communication of early adverse event reports from its MedWatch monitoring system as the agency reassesses its proposed Drug Watch website for emerging safety information

You may also be interested in...



FDA, MIT Collaborate On Development Of Active Drug Safety Surveillance Tool

FDA is working with the Massachusetts Institute of Technology's Center for Biomedical Innovation to develop an active drug safety surveillance system

FDA, MIT Collaborate On Development Of Active Drug Safety Surveillance Tool

FDA is working with the Massachusetts Institute of Technology's Center for Biomedical Innovation to develop an active drug safety surveillance system

Boxed Warnings, Drug Watch Are Policy Goals Of Drug Safety Oversight Board

FDA's Drug Safety Oversight Board should start shifting its focus toward broader policy questions - like standards for boxed warnings - in addition to addressing emerging safety issues for specific products, DSOB Executive Director Susan Cummins suggested

Related Content

Topics

UsernamePublicRestriction

Register

PS046643

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel